Ex­clu­sive: Su­do Bio­sciences se­cures $116M to start tri­als of its oral and top­i­cal TYK2 can­di­dates

Su­do Bio­sciences has raised a $116 mil­lion Se­ries B from well-known in­vestors and Sanofi’s VC arm, the transat­lantic biotech told End­points News, as it looks to cap­i­tal­ize on the TYK2 field fol­low­ing the lead of Bris­tol My­ers Squibb and Take­da (by way of Nim­bus Ther­a­peu­tics).

Carmel, IN-based Su­do is at­tempt­ing to carve a niche in the TYK2 space by cre­at­ing a brain-pen­e­trant oral drug that could po­ten­tial­ly treat con­di­tions such as mul­ti­ple scle­ro­sis, which hits close to home for CEO Scott Byrd, whose wife has lived with the dis­ease “for the bet­ter part of her life,” he said in an in­ter­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER